Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

We look at the continued turmoil within the FDA, including the forced dismissal of top gene therapy regulator Nicole Verdun, ...

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ...